We bring strategic capital, scientific acumen, and commercial discipline to innovations that:
Year Founded
Investments
Capital Invested
Team Members
Firm figures as of June 30, 2026.
80+ companies backed across biotechnology and medical technology since 2013, focused where clinical evidence meets commercial reality.
Proprietary research across private and public markets, pairing scientific depth with commercial judgment to inform every investment we make.
Deep relationships with strategic acquirers, industry leaders, and global capital markets, put to work on behalf of our companies.
Board-level engagement on positioning, capital structure, and exit — with the objective of converting funding into impactful innovation.
Our team combines scientific depth with commercial and capital markets expertise, seeking to engage directly in the success of the companies we back.
